PRRUF
Price:
$0.05
Market Cap:
$70.74M
Immutep Limited, an Australian biotechnology firm established in 1987, is focused on the discovery and development of innovative immunotherapeutic pharmaceuticals. The company's pipeline primarily targets cancer and autoimmune diseases. Its flagship product, eftilagimod alpha (also known as efti or IMP321), is currently in a Phase IIb clinical trial, investigating its efficacy as a chemo-immunotherapy combination for metastatic breast cancer. Additional oncology candidates include TACTI-002, undergoing Phase II trials for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer, and TACTI-003, in Phase IIb trials for HNSCC. The company is also evaluating INSIGHT-003 in a ...[Read more]
Industry
Biotechnology
IPO Date
2012-02-22
Stock Exchange
OTC
Ticker
PRRUF
According to Immutep Limited’s latest financial reports and current stock price. The company's current Current Ratio is 2.97. This represents a change of -77.03% compared to the average of 12.94 of the last 4 quarters.
The mean historical Current Ratio of Immutep Limited over the last ten years is 11.26. The current 2.97 Current Ratio has changed 2.54% with respect to the historical average. Over the past ten years (40 quarters), PRRUF's Current Ratio was at its highest in in the June 2011 quarter at 22.49. The Current Ratio was at its lowest in in the December 2007 quarter at 0.
Average
11.26
Median
12.25
Minimum
4.44
Maximum
18.25
Discovering the peaks and valleys of Immutep Limited Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 703.63%
Maximum Annual Current Ratio = 18.25
Minimum Annual Increase = -58.92%
Minimum Annual Current Ratio = 4.44
| Year | Current Ratio | Change |
|---|---|---|
| 2025 | 11.69 | -35.96% |
| 2024 | 18.25 | 32.12% |
| 2023 | 13.81 | -2.44% |
| 2022 | 14.16 | 10.50% |
| 2021 | 12.81 | 38.37% |
| 2020 | 9.26 | 108.42% |
| 2019 | 4.44 | -40.23% |
| 2018 | 7.43 | 22.90% |
| 2017 | 6.05 | -58.92% |
| 2016 | 14.72 | 703.63% |
The current Current Ratio of Immutep Limited (PRRUF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
14.58
5-year avg
14.14
10-year avg
11.26
Immutep Limited’s Current Ratio is greater than Cellectis S.A. (1.52), greater than CytoDyn Inc. (0.37), less than Transgene S.A. (9.62), greater than Northwest Biotherapeutics, Inc. (0.07), less than Clinuvel Pharmaceuticals Limited (14.64), less than Hansa Biopharma AB (publ) (3.63), greater than Frontage Holdings Corporation (1.33), less than Clinuvel Pharmaceuticals Limited (14.64), greater than Healios K.K. (2.05), less than Silence Therapeutics plc (9.83),
| Company | Current Ratio | Market cap |
|---|---|---|
| 1.52 | $251.93M | |
| 0.37 | $383.53M | |
| 9.62 | $122.57M | |
| 0.07 | $312.23M | |
| 14.64 | $307.51M | |
| 3.63 | $245.80M | |
| 1.33 | $223.05M | |
| 14.64 | $348.84M | |
| 2.05 | $193.79M | |
| 9.83 | $313.17M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immutep Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immutep Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Immutep Limited's Current Ratio?
How is the Current Ratio calculated for Immutep Limited (PRRUF)?
What is the highest Current Ratio for Immutep Limited (PRRUF)?
What is the 3-year average Current Ratio for Immutep Limited (PRRUF)?
What is the 5-year average Current Ratio for Immutep Limited (PRRUF)?
How does the current Current Ratio for Immutep Limited (PRRUF) compare to its historical average?